Vertex Pharmaceuticals’ Journavx (suzetrigine) has gained US Food and Drug Administration approval for acute pain, but the question now is how well it might fare commercially, with analysts forecasting some potential challenges.
The FDA approved Journavx on 30 January for moderate to severe acute pain in adults. Vertex called the drug the first and only non-opioid oral pain signal inhibitor and the first new class of pain drugs to win FDA approval in more than 20 years
Key Takeaways
- The FDA approved Vertex’s Journavx for moderate to severe acute pain in adults, the first new class of pain medication in more than 20 years.
- The company is giving the drug a wholesale acquisition cost of $15.50 per pill or $31 per day, but hopes that it’s not being an opioid will make up for the much higher price
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
